Pioglitazone
- Generic Name
- Pioglitazone
- Brand Names
- Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N2O3S
- CAS Number
- 111025-46-8
- Unique Ingredient Identifier
- X4OV71U42S
- Background
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...
- Indication
Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.
- Associated Conditions
- Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
- Associated Therapies
- -
"Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat
- Conditions
- First Posted Date
- 2006-09-19
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Pennington Biomedical Research Center
- Target Recruit Count
- 96
- Registration Number
- NCT00377975
- Locations
- 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
PIoglitazone for PrEvention of Restenosis in Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2006-09-15
- Last Posted Date
- 2008-08-01
- Lead Sponsor
- University of Rome Tor Vergata
- Target Recruit Count
- 160
- Registration Number
- NCT00376870
- Locations
- 🇮🇹
Policlinico di Tor Vergata, Rome, Italy
Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2006-09-14
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 96
- Registration Number
- NCT00376181
Metabolic Effects of Thiazolidinediones in Chronic Kidney Disease
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2010-11-03
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 12
- Registration Number
- NCT00368017
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia
- First Posted Date
- 2006-05-31
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- Takeda
- Target Recruit Count
- 719
- Registration Number
- NCT00331487
Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.
- Conditions
- Interventions
- First Posted Date
- 2006-05-22
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1554
- Registration Number
- NCT00328627
Effect of Pioglitazone on Ambulatory Blood Pressure
- Conditions
- Interventions
- First Posted Date
- 2006-05-19
- Last Posted Date
- 2012-07-10
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 2
- Registration Number
- NCT00328393
- Locations
- 🇩🇪
CRC Medical Department IV, Erlangen, Germany
A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
- Conditions
- Interventions
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1306
- Registration Number
- NCT00327015
- Locations
- 🇺🇸
Newark Physician Associates, Newark, Ohio, United States
🇺🇸East Bay Clinical Trial Center, Concord, California, United States
🇺🇸Community Clinical Trials, Orange, California, United States
Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease
- First Posted Date
- 2006-05-08
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Target Recruit Count
- 21
- Registration Number
- NCT00322868
- Locations
- 🇺🇸
Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
Optimizing Body Composition for Function in Older Adults
- First Posted Date
- 2006-04-17
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 88
- Registration Number
- NCT00315146
- Locations
- 🇺🇸
Sticht Center on Aging, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.